Quanterix Corporation

Quanterix is a life sciences company that develops and markets ultra-sensitive digital immunoassay platforms for research and diagnostics. Its proprietary Simoa (Single Molecule Array) technology enables the detection and quantification of protein biomarkers at concentrations far below the limits of traditional immunoassay methods, facilitating breakthroughs in neurology, oncology, cardiology, immunology, and infectious disease research. In 2025, Quanterix expanded its capabilities by acquiring Akoya Biosciences, integrating multiplexed tissue imaging with its blood-based biomarker detection platforms. This combined portfolio allows for a uniquely integrated approach to precision medicine, connecting biology across both blood and tissue from discovery through to clinical diagnostics.